Immersion

Does MDMA-assisted therapy help with PTSD?

Last updated

Short answer

In two phase 3 trials, people with PTSD who did a course of talk therapy paired with a small number of supervised MDMA sessions improved more than those who did the same therapy with a placebo. Most no longer met the criteria for PTSD. But it stays investigational, and regulators have asked for more study.

The research
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot'alora G., M., and colleagues (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, volume 27, issue 6, pages 1025 to 1033.
Sample 90 adults with severe PTSD across sites in the United States, Canada, and Israel, in a randomized, double-blind, placebo-controlled phase 3 trial
Published 2021
Journal Nature Medicine
Jennifer Mitchell and a large team ran this trial, one of the first of its kind at this scale, across sites in the United States, Canada, and Israel. They enrolled 90 adults with severe post-traumatic stress disorder, or PTSD, a condition that can follow a frightening or overwhelming event and leave a person with flashbacks, broken sleep, and a nervous system stuck on high alert. Everyone received the same structured course of talk therapy: preparation sessions first, then a few long supervised sessions, then integration sessions afterward to make sense of what came up. Participants were randomly split in half. One half received MDMA during the long sessions, and the other half received an inactive placebo, with neither the participants nor the independent raters told which. Symptoms were tracked with a standard clinician-rated scale called the CAPS-5, where a higher score means more severe PTSD, and the group started around 44. At the end of the roughly eighteen-week trial, the MDMA group had fallen about 24 points on that scale, compared with about 14 points in the placebo group. Put another way, 67 percent of the MDMA group no longer met the criteria for a PTSD diagnosis, against 32 percent of the placebo group. The authors were careful about the limits. Many people could tell whether they had received MDMA, which can color the results, and the trial was sponsored by a nonprofit organization that has long worked to advance this treatment.
Read the paper

What does this mean for you?

Here is the plain version. For people with severe PTSD, a structured course of therapy that included a few supervised MDMA sessions helped more than the same therapy with a placebo, and the size of the difference was real rather than trivial. In a field where many people stay stuck for years, two thirds of the MDMA group no longer meeting the criteria for the diagnosis is a striking number. A second, larger trial a couple of years later pointed the same way, which matters, because one promising study can be a fluke and two moving together is harder to wave away.

The honest part is just as important. The thing that was tested was not a substance on its own. It was a whole package: careful preparation, long sessions with a trained therapy team present the entire time, and integration work afterward. The medicine and the therapy were studied together, so the result belongs to the combination, not to MDMA alone. Reading it as a drug that fixes PTSD by itself would miss what the trials actually did.

There is also a real question mark hanging over the results. In both trials, a lot of people could guess whether they had received MDMA or a placebo, because the experience is hard to mistake. When people can tell which group they are in, their hopes and expectations can nudge the scores, and that makes a strong result harder to trust at face value. The placebo group improved a fair amount too, which is a reminder that the attention, the structure, and the therapy itself carry weight on their own.

This is why the treatment is still investigational. The positive trials were not the end of the story. In 2024, United States regulators declined to approve MDMA-assisted therapy for PTSD and asked for more research, pointing to questions about how lasting the benefit is and about that unblinding problem. So the fair summary is this: a promising, carefully studied approach with encouraging results, not a settled or widely available treatment, and only ever something done under close professional supervision.

The takeaway

Terms in this page
Set and setting Integration Between-session support

This is the work Asendar™ was built for: the stretch after an intense session, when the task is to hold on to what opened up and to notice honestly how you are doing day to day. If you want a simple read on where your head is starting from today, take your Mental Readiness Score.

Start free: get your Mental Readiness Score

Your Mental Readiness Score is a short daily check-in on how steady you feel today. Free, web app, no download.

People also ask

What happens during an MDMA therapy session for PTSD?

In the trials, the sessions with the medicine were long and supervised, with a trained therapy team present the whole time. They did not stand alone. Preparation sessions came first, and integration sessions came afterward to help make sense of what surfaced. The session itself was one part of a longer course of therapy.

Did a second trial find the same thing?

Yes. A second, larger phase 3 trial published in 2023, with 104 people who had moderate to severe PTSD, pointed the same way. About 71 percent of the MDMA-assisted therapy group no longer met the criteria for PTSD, against about 48 percent of those who had therapy with a placebo, and no serious safety problems were reported in either group.

Is MDMA-assisted therapy approved for PTSD?

No. Despite the positive trials, United States regulators declined to approve it in 2024 and asked for more research, citing questions about how lasting the benefit is and the fact that people often knew whether they had received MDMA. It remains investigational and is not a treatment you can simply sign up for.

Explore more in the Immersion pillar